Héctor Soto Parrà

Also affiliated with Policlinico Universitario di Catania, Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)”.

1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1371

N/A

0DataRank · unranked

2 citations

Luis Paz‐Ares, M.C. Garassino, Shobhit Baijal, J. Bennouna, D.B. Daniel +12 more